{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:39:22Z","timestamp":1791931162406,"version":"4.3.4"},"reference-count":259,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1002\/hep.30145","type":"journal-article","created":{"date-parts":[[2018,8,5]],"date-time":"2018-08-05T21:03:01Z","timestamp":1533502981000},"page":"394-419","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":850,"title":["Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases"],"prefix":"10.1097","volume":"69","author":[{"given":"Keith D.","family":"Lindor","sequence":"first","affiliation":[{"name":"Arizona State University,Division of Gastroenterology and Hepatology,Mayo Clinic,Phoenix,AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[{"name":"University of California,Davis, Sacramento,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Boyer","sequence":"additional","affiliation":[{"name":"Yale School of Medicine,New Haven,CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[{"name":"University of Miami,Miami,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn","family":"Mayo","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center,Dallas,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"hep30145-bib-0001-20250401","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.clinre.2015.08.001","article-title":"Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'","volume":"39","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"hep30145-bib-0003-20250401","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":". Primary biliary cirrhosis","volume":"377","year":"2011","journal-title":"Lancet"},{"key":"hep30145-bib-0004-20250401","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0016-5085(95)90469-7","article-title":"American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers","volume":"108","year":"1995","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0005-20250401","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary biliary cirrhosis in monzygotic and dizygotic twins: Genetics, epigenetics, and environment","volume":"127","year":"2004","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0006-20250401","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.3748\/wjg.v23.i39.7191","article-title":"Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis","volume":"23","year":"2017","journal-title":"World J Gastroenterol"},{"key":"hep30145-bib-0007-20250401","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0037-1603324","article-title":"Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis","volume":"37","year":"2017","journal-title":"Semin Liver Dis"},{"key":"hep30145-bib-0008-20250401","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4049\/jimmunol.138.10.3525","article-title":"Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis","volume":"138","year":"1987","journal-title":"J Immunol"},{"key":"hep30145-bib-0009-20250401","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.510230307","article-title":"Epitope mapping and reactivity of autoantibodies to the E2 component of 2\u2010oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2\u2010oxoglutarate dehydrogenase complex","volume":"23","year":"1996","journal-title":"Hepatology"},{"key":"hep30145-bib-0010-20250401","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and functional analysis of PDC\u2010E2\u2010specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis","volume":"109","year":"2002","journal-title":"J Clin Invest"},{"key":"hep30145-bib-0011-20250401","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1172\/JCI4213","article-title":"Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis","volume":"102","year":"1998","journal-title":"J Clin Invest"},{"key":"hep30145-bib-0012-20250401","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1093\/hmg\/dds359","article-title":"Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q1, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants","volume":"21","year":"2012","journal-title":"Hum Mol Genet"},{"key":"hep30145-bib-0013-20250401","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first\u2010line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK\u2010FL study","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"hep30145-bib-0014-20250401","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0015-20250401","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1038\/ncomms9019","article-title":"International genome\u2010wide meta\u2010analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways","volume":"6","year":"2015","journal-title":"Nat Commun"},{"key":"hep30145-bib-0016-20250401","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.789","article-title":"Genome\u2010wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis","volume":"43","year":"2011","journal-title":"Nat Genet"},{"key":"hep30145-bib-0017-20250401","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ng.627","article-title":"Genome\u2010wide meta\u2010analyses identify three loci associated with primary biliary cirrhosis","volume":"42","year":"2010","journal-title":"Nat Genet"},{"key":"hep30145-bib-0018-20250401","doi-asserted-by":"crossref","first-page":"14828","DOI":"10.1038\/ncomms14828","article-title":"A genome\u2010wide association study identifies six novel risk loci for primary biliar cholangitis","volume":"8","year":"2017","journal-title":"Nat Commun"},{"key":"hep30145-bib-0019-20250401","article-title":"Yttrium\u201090 microsphere radioembolisation for unresectable hepatocellular carcinoma","volume":"1\u201031","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"hep30145-bib-0020-20250401","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ajhg.2012.08.010","article-title":"Genome\u2010wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population","volume":"91","year":"2012","journal-title":"Am J Hum Genet"},{"key":"hep30145-bib-0021-20250401","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/ng.2395","article-title":"Dense fine\u2010mapping study identifies new susceptibility loci for primary biliary cirrhosis","volume":"44","year":"2012","journal-title":"Nat Genet"},{"key":"hep30145-bib-0022-20250401","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.dld.2013.01.028","article-title":"Questionaire based assessment of risk factors for primary biliary cirrhosis","volume":"45","year":"2013","journal-title":"Dig Liver Dis"},{"key":"hep30145-bib-0023-20250401","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/gut.2009.184218","article-title":"Case\u2010control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations","volume":"59","year":"2010","journal-title":"Gut"},{"key":"hep30145-bib-0024-20250401","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","article-title":"Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview\u2010based study of 1032 patients","volume":"42","year":"2005","journal-title":"Hepatology"},{"key":"hep30145-bib-0025-20250401","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/hep.21076","article-title":"Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep30145-bib-0026-20250401","first-page":"e200","article-title":"Geoepidemiology and space\u2010time analysis of Primary biliary cirrhosis in Crete","volume":"34","year":"2014","journal-title":"Greece. Liver Int"},{"key":"hep30145-bib-0027-20250401","first-page":"2052","article-title":"Screening of antimitochondrial antibody subtype M2 in residents at least 18 years of age in an urban district of Shanghai","volume":"20","year":"2016","journal-title":"China. Eur Rev Med Pharmacol Sci"},{"key":"hep30145-bib-0028-20250401","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwt308","article-title":"No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England","volume":"179","year":"2014","journal-title":"Am J Epidemiol"},{"key":"hep30145-bib-0029-20250401","first-page":"128","article-title":"Genome\u2010wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis","volume":"5","year":"2014","journal-title":"Front Immunol"},{"key":"hep30145-bib-0030-20250401","first-page":"172","article-title":"Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial","volume":"33","year":"2014","journal-title":"J Clin Oncol"},{"key":"hep30145-bib-0031-20250401","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/hep.29245","article-title":"Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep30145-bib-0032-20250401","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.4049\/jimmunol.179.4.2651","article-title":"Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization","volume":"179","year":"2007","journal-title":"J Immunol"},{"key":"hep30145-bib-0033-20250401","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.22390","article-title":"Loss of tolerance in C57BL\/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep30145-bib-0034-20250401","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hep.24355","article-title":"Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"hep30145-bib-0035-20250401","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/hep.21871","article-title":"Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep30145-bib-0036-20250401","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0168-8278(99)80097-X","article-title":"Familial primary biliary cirrhosis reassessed: a geographically\u2010based population study","volume":"30","year":"1999","journal-title":"J Hepatol"},{"key":"hep30145-bib-0037-20250401","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary bililary cirrhosis: A systematic review","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"hep30145-bib-0038-20250401","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.510270303","article-title":"Characterization of antimitochondrial antibodies in health adults","volume":"27","year":"1998","journal-title":"Hepatology"},{"key":"hep30145-bib-0039-20250401","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00535-003-1285-6","article-title":"Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture","volume":"39","year":"2004","journal-title":"J Gastroenterol"},{"key":"hep30145-bib-0040-20250401","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large\u2010scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep30145-bib-0041-20250401","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(96)04410-8","article-title":"Natural history of early primary biliary cirrhosis","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"hep30145-bib-0042-20250401","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30145-bib-0043-20250401","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.21749","article-title":"Increased prevalence of antimitochondrial antibodies in first\u2010degree relatives of patients with primary biliary cirrhosis","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep30145-bib-0044-20250401","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0016-5085(77)80011-5","article-title":"Presentation and course of asymptomatic primary biliary cirrhosis","volume":"72","year":"1977","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0045-20250401","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0168-8278(05)80139-4","article-title":"Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years","volume":"20","year":"1994","journal-title":"J Hepatol"},{"key":"hep30145-bib-0046-20250401","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0016-5085(90)90968-7","article-title":"Symptom development and prognosis in primary biliary cirrhosis: a study in two centers","volume":"99","year":"1990","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0047-20250401","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/00365528909092240","article-title":"Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease","volume":"24","year":"1989","journal-title":"Scand J Gastroenterol"},{"key":"hep30145-bib-0048-20250401","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow\u2010up for up to 28 years","volume":"123","year":"2002","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0049-20250401","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","article-title":"Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis","volume":"94","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0050-20250401","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis","volume":"308","year":"1983","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0051-20250401","first-page":"1166","article-title":"Association between fatigue and decreased survival in primary biliary cirrhosis","volume":"56","year":"2007","journal-title":"Gut"},{"key":"hep30145-bib-0052-20250401","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial","volume":"89","year":"1985","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0053-20250401","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","year":"2000","journal-title":"Hepatology"},{"key":"hep30145-bib-0054-20250401","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","year":"1996","journal-title":"Hepatology"},{"key":"hep30145-bib-0055-20250401","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/0016-5085(89)90526-X","article-title":"Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival","volume":"96","year":"1989","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0056-20250401","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long\u2010term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","year":"1999","journal-title":"Hepatology"},{"key":"hep30145-bib-0057-20250401","first-page":"759","article-title":"A randomized, double\u2010blind, placebo\u2010controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","year":"1995","journal-title":"Hepatology"},{"key":"hep30145-bib-0058-20250401","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double\u2010blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","year":"1994","journal-title":"Hepatology"},{"key":"hep30145-bib-0059-20250401","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis","volume":"110","year":"1996","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0060-20250401","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long\u2010term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0061-20250401","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA\u2010PBC Study Group","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0062-20250401","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long\u2010term treatment of primary biliary cirrhosis. The UDCA\u2010PBC Study Group","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0063-20250401","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","year":"1997","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0064-20250401","first-page":"1668","article-title":"Ten\u2010year survival in ursodeoxycholic acid\u2010treated patients with primary biliary cirrhosis","volume":"29","year":"1999","journal-title":"The UDCA\u2010PBC Study Group. Hepatology"},{"key":"hep30145-bib-0065-20250401","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","year":"2003","journal-title":"J Hepatol"},{"key":"hep30145-bib-0066-20250401","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A placebo\u2010controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid","volume":"108","year":"1995","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0067-20250401","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","year":"2005","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0068-20250401","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol\u2010treated patients","volume":"122","year":"2002","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0069-20250401","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"hep30145-bib-0070-20250401","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0016-5085(86)90972-8","article-title":"Azathioprine and prognosis in primary biliary cirrhosis","volume":"90","year":"1986","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0071-20250401","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","year":"1989","journal-title":"Hepatology"},{"key":"hep30145-bib-0072-20250401","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12072-017-9819-9","article-title":"A brief review on prognostic models of primary biliary cholangitis","volume":"11","year":"2017","journal-title":"Hepatol Int"},{"key":"hep30145-bib-0073-20250401","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.dld.2016.05.023","article-title":"Toward precision medicine in primary biliary cholangitis","volume":"48","year":"2016","journal-title":"Dig Liver Dis"},{"key":"hep30145-bib-0074-20250401","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0075-20250401","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK\u2010PBC risk scores: Derivation and validation of a scoring system for long\u2010term prediction of end\u2010stage liver disease in primary biliary cholangitis","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep30145-bib-0076-20250401","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.1840100516","article-title":"Extramural cross\u2010validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability","volume":"10","year":"1989","journal-title":"Hepatology"},{"key":"hep30145-bib-0077-20250401","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow\u2010up study","volume":"147","year":"2014","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0078-20250401","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","year":"1999","journal-title":"Liver"},{"key":"hep30145-bib-0079-20250401","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","year":"2012","journal-title":"Liver Int"},{"key":"hep30145-bib-0080-20250401","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography\u2010based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"hep30145-bib-0081-20250401","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/cgh.2003.50014","article-title":"When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?","volume":"1","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30145-bib-0082-20250401","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1478-3231.2004.0918.x","article-title":"Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA\u2010treated patients with primary biliary cirrhosis","volume":"24","year":"2004","journal-title":"Liver Int"},{"key":"hep30145-bib-0083-20250401","first-page":"408","article-title":"Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis","volume":"30","year":"1999","journal-title":"UDCA\u2010PBC Group. J Hepatol"},{"key":"hep30145-bib-0084-20250401","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","article-title":"Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review","volume":"194","year":"2007","journal-title":"Atherosclerosis"},{"key":"hep30145-bib-0085-20250401","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0086-20250401","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti\u2010gp210 and anti\u2010centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep30145-bib-0087-20250401","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12016-010-8234-y","article-title":"Overcoming a \u201cprobable\u201d diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature","volume":"42","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"hep30145-bib-0088-20250401","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis","volume":"35","year":"2015","journal-title":"Liver Int"},{"key":"hep30145-bib-0089-20250401","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.510290444","article-title":"Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression","volume":"29","year":"1999","journal-title":"Hepatology"},{"key":"hep30145-bib-0090-20250401","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement","volume":"60","year":"2010","journal-title":"Pathol Int"},{"key":"hep30145-bib-0091-20250401","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/MCG.0b013e3181f18c4e","article-title":"Varices in early histological stage primary biliary cirrhosis","volume":"45","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"hep30145-bib-0092-20250401","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.21151","article-title":"Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep30145-bib-0093-20250401","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cld.2015.08.013","article-title":"Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases","volume":"20","year":"2016","journal-title":"Clin Liver Dis"},{"key":"hep30145-bib-0094-20250401","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"A 2\u2010year multicenter, double\u2010blind, randomized, placebo\u2010controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep30145-bib-0095-20250401","first-page":"628A","article-title":"Modafinil is effective treatment for excessive daytime somnolence and fatigue in primary biliary cirrhosis [Abstract]","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep30145-bib-0096-20250401","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.20276","article-title":"Quality of life in patients with primary biliary cirrhosis","volume":"40","year":"2004","journal-title":"Hepatology"},{"key":"hep30145-bib-0097-20250401","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.2005.080317","article-title":"Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort","volume":"55","year":"2006","journal-title":"Gut"},{"issue":"Suppl 2","key":"hep30145-bib-0098-20250401","first-page":"109","article-title":"Fatigue in primary biliary cirrhosis: prevalence, pathogenesis and management","volume":"33","year":"2015","journal-title":"Dig Dis"},{"key":"hep30145-bib-0099-20250401","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2007.01.036","article-title":"Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis","volume":"46","year":"2007","journal-title":"J Hepatol"},{"key":"hep30145-bib-0100-20250401","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort","volume":"53","year":"2004","journal-title":"Gut"},{"key":"hep30145-bib-0101-20250401","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis","volume":"1","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30145-bib-0102-20250401","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1089-3261(03)00100-4","article-title":"Natural history of primary biliary cirrhosis","volume":"7","year":"2003","journal-title":"Clin Liver Dis"},{"key":"hep30145-bib-0103-20250401","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0016-5085(19)31870-0","article-title":"Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus","volume":"73","year":"1977","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0104-20250401","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.1840110526","article-title":"The pruritus of cholestasis: from bile acids to opiate agonists","volume":"11","year":"1990","journal-title":"Hepatology"},{"key":"hep30145-bib-0105-20250401","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"hep30145-bib-0106-20250401","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1365-2044.1989.tb09116.x","article-title":"The incidence of pruritus after epidural morphine","volume":"44","year":"1989","journal-title":"Anaesthesia"},{"key":"hep30145-bib-0107-20250401","first-page":"367","article-title":"Prophylactic oral naltrexone with intrathecal morphine for cesarean section: effects on adverse reactions and analgesia","volume":"71","year":"1990","journal-title":"Anesth Analg"},{"key":"hep30145-bib-0108-20250401","first-page":"1840","article-title":"The natural history of abdominal pain associated with primary biliary cirrhosis","volume":"89","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0109-20250401","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","article-title":"Extrahepatic autoimmune conditions associated with primary biliary cirrhosis","volume":"48","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"hep30145-bib-0110-20250401","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jcla.20130","article-title":"Low specificity of anti\u2010tissue transglutaminase antibodies in patients with primary biliary cirrhosis","volume":"20","year":"2006","journal-title":"J Clin Lab Anal"},{"key":"hep30145-bib-0111-20250401","first-page":"247","article-title":"Antimitochondrial antibody\u2010negative primary biliary cirrhosis","volume":"90","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0112-20250401","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/gut.35.2.260","article-title":"Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis","volume":"35","year":"1994","journal-title":"Gut"},{"key":"hep30145-bib-0113-20250401","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.510250507","article-title":"Comparison of the clinical features and clinical course of antimitochondrial antibody\u2010positive and \u2010negative primary biliary cirrhosis","volume":"25","year":"1997","journal-title":"Hepatology"},{"key":"hep30145-bib-0114-20250401","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2188\/jea.16.30","article-title":"Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid","volume":"16","year":"2006","journal-title":"J Epidemiol"},{"key":"hep30145-bib-0115-20250401","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3109\/00365521.2015.1132337","article-title":"Long\u2010term outcomes in antimitochondrial antibody negatve primary biliary cirrhosis","volume":"51","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"hep30145-bib-0116-20250401","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clinre.2015.10.006","article-title":"Assessment of health related quality of life in polish patients with primary biliary cirrhosis","volume":"40","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"hep30145-bib-0117-20250401","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00000478-199401000-00009","article-title":"Primary autoimmune cholangitis. An alternative to antimitochondrial antibody\u2010negative primary biliary cirrhosis","volume":"18","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"hep30145-bib-0118-20250401","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.25511","article-title":"Comparitivie analysis of portal cell infiltrates in antimitochondrial autoantibody\u2010positive versus antimitochondrial autoantibody\u2010negative primary biiary cirrhosis","volume":"55","year":"2012","journal-title":"Hepatology"},{"key":"hep30145-bib-0119-20250401","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MEG.0000000000000075","article-title":"Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis","volume":"26","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep30145-bib-0120-20250401","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1478-3231.2007.01538.x","article-title":"Development of autoimmune hepatitis in primary biliary cirrhosis","volume":"27","year":"2007","journal-title":"Liver Int"},{"key":"hep30145-bib-0121-20250401","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep30145-bib-0122-20250401","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","year":"1999","journal-title":"J Hepatol"},{"key":"hep30145-bib-0123-20250401","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1572-0241.2002.05703.x","article-title":"Overlap of autoimmue hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system","volume":"97","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0124-20250401","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1746.2004.03372.x","article-title":"Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome","volume":"19","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"hep30145-bib-0125-20250401","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2009.616","article-title":"Autoimmune hepatitis\u2010PBC overlap syndrome: a simplified scoring system may assist in the diagnosis","volume":"105","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0126-20250401","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/1751-2980.12196","article-title":"Primary biliary cirrhosis\u2010autoimmune hepatitis overlap syndrome: simplified criteria may be effective in the diagnosis in Chinese patients","volume":"15","year":"2014","journal-title":"J Dig Dis"},{"key":"hep30145-bib-0127-20250401","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis\u2010autoimmune hepatitis overlap syndrome: Clinical features and response to therapy","volume":"28","year":"1998","journal-title":"Hepatology"},{"key":"hep30145-bib-0128-20250401","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.510290409","article-title":"Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals","volume":"29","year":"1999","journal-title":"Hepatology"},{"key":"hep30145-bib-0129-20250401","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/jhep.2002.30902","article-title":"Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid","volume":"35","year":"2002","journal-title":"Hepatology"},{"key":"hep30145-bib-0130-20250401","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0399-8320(07)89323-7","article-title":"Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease","volume":"31","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"hep30145-bib-0131-20250401","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2013.12.010","article-title":"Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non\u2010Hispanics","volume":"12","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30145-bib-0132-20250401","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","article-title":"The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis","volume":"50","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"hep30145-bib-0133-20250401","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cgh.2011.03.019","article-title":"Prevalence of primary biliary cirrhosis\u2010autoimmune hepatitis overlap syndrome","volume":"9","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30145-bib-0134-20250401","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long\u2010term outcomes","volume":"102","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0135-20250401","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis\u2010autoimmune hepatitis overlap syndrome","volume":"44","year":"2006","journal-title":"J Hepatol"},{"key":"hep30145-bib-0136-20250401","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.22380","article-title":"Long\u2010term follow\u2010up of antimitochondrial antibody\u2010positive autoimmune hepatitis","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep30145-bib-0137-20250401","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1478-3231.2004.0924.x","article-title":"Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis","volume":"24","year":"2004","journal-title":"Liver Int"},{"key":"hep30145-bib-0138-20250401","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1440-1746.2006.04130.x","article-title":"Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial\/anti\u2010M2 seropositive variant form of autoimmune hepatitis","volume":"21","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"hep30145-bib-0139-20250401","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.1440-1746.2006.04434.x","article-title":"Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis","volume":"21","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"hep30145-bib-0140-20250401","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/MEG.0000000000000870","article-title":"Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study","volume":"29","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep30145-bib-0141-20250401","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"hep30145-bib-0142-20250401","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic\u2010acid therapy for primary biliary cirrhosis: a meta\u2010analysis","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"hep30145-bib-0143-20250401","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta\u2010analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0144-20250401","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cgh.2007.07.015","article-title":"Transplantation trends in primary biliary cirrhosis","volume":"5","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30145-bib-0145-20250401","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial","volume":"30","year":"1999","journal-title":"J Hepatol"},{"key":"hep30145-bib-0146-20250401","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1046\/j.1365-2036.2000.00817.x","article-title":"Bioavailability of four ursodeoxycholic acid preparations","volume":"14","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30145-bib-0147-20250401","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJM197406062902326","article-title":"Letter: Timing of cholestyramine doses in cholestatic liver disease","volume":"290","year":"1974","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0148-20250401","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","article-title":"Characterisation of patients with a complete biochemical response to ursodeoxycholic acid","volume":"36","year":"1995","journal-title":"Gut"},{"key":"hep30145-bib-0149-20250401","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long\u2010term prognosis in primary biliary cirrhosis","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep30145-bib-0150-20250401","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","year":"2009","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0151-20250401","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long\u2010term histological progression in primary biliary cirrhosis","volume":"105","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0152-20250401","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long\u2010term outcome","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"hep30145-bib-0153-20250401","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(12)61815-1","article-title":"Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis","volume":"69","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"hep30145-bib-0154-20250401","first-page":"389","article-title":"Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?","volume":"21","year":"1995","journal-title":"Hepatology"},{"key":"hep30145-bib-0155-20250401","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00004836-200308000-00018","article-title":"Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis","volume":"37","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"hep30145-bib-0156-20250401","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1\u2010ethyl\u2010chenodeoxycholic acid (6\u2010ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","year":"2002","journal-title":"J Med Chem"},{"key":"hep30145-bib-0157-20250401","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile\u2010acid signalling for metabolic diseases","volume":"7","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"1 Suppl","key":"hep30145-bib-0158-20250401","first-page":"S25","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR","volume":"62","year":"2015","journal-title":"PXR and beyond. J Hepatol"},{"key":"hep30145-bib-0159-20250401","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148:","year":"2015","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0160-20250401","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep30145-bib-0161-20250401","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo\u2010controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0162-20250401","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long\u2010term clinical impact and cost\u2010effectiveness of obeticholic acid for the treatment of primary biliary cholangitis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep30145-bib-0163-20250401","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.20103","article-title":"A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten\u2010year results","volume":"39","year":"2004","journal-title":"Hepatology"},{"key":"hep30145-bib-0164-20250401","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep30145-bib-0165-20250401","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30145-bib-0166-20250401","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0167-20250401","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","year":"2007","journal-title":"Am J Cardiol"},{"key":"hep30145-bib-0168-20250401","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0016-5085(86)90183-6","article-title":"Randomized trial of chlorambucil for primary biliary cirrhosis","volume":"91","year":"1986","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0169-20250401","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM198504183121602","article-title":"Trial of penicillamine in advanced primary biliary cirrhosis","volume":"312","year":"1985","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0170-20250401","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/gut.26.2.114","article-title":"Double blind controlled trial of d\u2010penicillamine in patients with primary biliary cirrhosis","volume":"26","year":"1985","journal-title":"Gut"},{"key":"hep30145-bib-0171-20250401","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","article-title":"A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis","volume":"322","year":"1990","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0172-20250401","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0016-5085(93)90422-9","article-title":"Cyclosporin A treatment in primary biliary cirrhosis: results of a long\u2010term placebo controlled trial","volume":"104","year":"1993","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0173-20250401","first-page":"336","article-title":"A controlled trial of prednisolone treatment in primary biliary cirrhosis","volume":"15","year":"1992","journal-title":"Three\u2010year results. J Hepatol"},{"key":"hep30145-bib-0174-20250401","first-page":"168","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"hep30145-bib-0175-20250401","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","article-title":"Low\u2010dose methotrexate is ineffective in primary biliary cirrhosis: Long\u2010term results of a placebo\u2010controlled trial","volume":"117","year":"1999","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0176-20250401","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM198612043152304","article-title":"A prospective trial of colchicine for primary biliary cirrhosis","volume":"315","year":"1986","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0177-20250401","first-page":"CD004481","article-title":"Gluud C. Colchicine for primary biliary cirrhosis","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"hep30145-bib-0178-20250401","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/jhep.2000.18663","article-title":"Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"32","year":"2000","journal-title":"Hepatology"},{"key":"hep30145-bib-0179-20250401","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/j.1572-0241.2001.05270.x","article-title":"Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?","volume":"96","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0180-20250401","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","year":"2000","journal-title":"Hepatology"},{"key":"hep30145-bib-0181-20250401","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX\u20108025), a selective PPAR\u2010delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double\u2010blind, randomised, placebo\u2010controlled, phase 2, proof\u2010of\u2010concept study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep30145-bib-0182-20250401","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK\u2010PBC national study","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep30145-bib-0183-20250401","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(99)02936-0","article-title":"Relief from profound fatigue associated with chronic liver disease by long\u2010term ondansetron therapy","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"hep30145-bib-0184-20250401","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/hep.20698","article-title":"A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep30145-bib-0185-20250401","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s10620-006-9397-5","article-title":"Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double\u2010blind controlled trial","volume":"51","year":"2006","journal-title":"Dig Dis Sci"},{"key":"hep30145-bib-0186-20250401","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-143-7-200510040-00024","article-title":"Modafinil for the treatment of fatigue in primary biliary cirrhosis","volume":"143","year":"2005","journal-title":"Ann Intern Med"},{"key":"hep30145-bib-0187-20250401","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","article-title":"An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis","volume":"25","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30145-bib-0188-20250401","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000387","article-title":"A randomized, placebo\u2010controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"24","year":"2017","journal-title":"Am J Ther"},{"key":"hep30145-bib-0189-20250401","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.04.017","article-title":"The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study","volume":"59","year":"2013","journal-title":"J Hepatol"},{"key":"hep30145-bib-0190-20250401","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","article-title":"Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis","volume":"50","year":"1966","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0191-20250401","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJM196109072651004","article-title":"The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine","volume":"265","year":"1961","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0192-20250401","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double\u2010blind, randomized, placebo\u2010controlled trial","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"hep30145-bib-0193-20250401","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF00544371","article-title":"Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis","volume":"28","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"hep30145-bib-0194-20250401","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double\u2010blind, crossover, randomized trial","volume":"94","year":"1988","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0195-20250401","first-page":"574","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","year":"1989","journal-title":"Lancet"},{"key":"hep30145-bib-0196-20250401","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF01300759","article-title":"Treatment of pruritus of primary biliary cirrhosis with rifampin","volume":"36","year":"1991","journal-title":"Dig Dis Sci"},{"key":"hep30145-bib-0197-20250401","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis\u2010associated pruritus","volume":"102","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0198-20250401","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta\u2010analysis of prospective randomized\u2010controlled trials","volume":"26","year":"2006","journal-title":"Liver Int"},{"key":"hep30145-bib-0199-20250401","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","year":"2002","journal-title":"Gut"},{"key":"hep30145-bib-0200-20250401","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200002000-00023","article-title":"Rifampin\u2010induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline","volume":"20","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"hep30145-bib-0201-20250401","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","article-title":"Effects of naloxone infusions in patients with the pruritus of cholestasis. A double\u2010blind, randomized, controlled trial","volume":"123","year":"1995","journal-title":"Ann Intern Med"},{"key":"hep30145-bib-0202-20250401","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/bmj.297.6662.1501","article-title":"Opioid peptides and primary biliary cirrhosis","volume":"297","year":"1988","journal-title":"BMJ"},{"key":"hep30145-bib-0203-20250401","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0190-9622(99)70117-9","article-title":"Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study","volume":"41","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"hep30145-bib-0204-20250401","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.510270307","article-title":"Open\u2010label trial of oral nalmefene therapy for the pruritus of cholestasis","volume":"27","year":"1998","journal-title":"Hepatology"},{"key":"hep30145-bib-0205-20250401","first-page":"1022","article-title":"Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease","volume":"91","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0206-20250401","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0016-5085(03)00879-5","article-title":"Pain as a complication of use of opiate antagonists for symptom control in cholestasis","volume":"125","year":"2003","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0207-20250401","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Veterans Affairs Naltrexone Cooperative Study G. Naltrexone in the treatment of alcohol dependence","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0208-20250401","first-page":"1215","article-title":"Naltrexone and hepatotoxicity","volume":"1","year":"1986","journal-title":"Lancet"},{"key":"hep30145-bib-0209-20250401","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first\u2010line treatment for cholestatic pruritus","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep30145-bib-0210-20250401","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199405263302117","article-title":"Ondansetron for pruritus due to cholestasis","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"hep30145-bib-0211-20250401","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/0140-6736(93)91178-O","article-title":"Improvement of cholestatic pruritus by ondansetron","volume":"341","year":"1993","journal-title":"Lancet"},{"key":"hep30145-bib-0212-20250401","first-page":"1196","article-title":"Ondansetron and pruritus in chronic liver disease: a controlled study","volume":"54","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"hep30145-bib-0213-20250401","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7326\/0003-4819-82-3-310","article-title":"Phenobartial effectis in cholestatic liver disease","volume":"82","year":"1975","journal-title":"Ann Intern Med"},{"key":"hep30145-bib-0214-20250401","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2340\/00015555-0350","article-title":"Itch in primary biliary cirrhosis: a patients' perspective","volume":"88","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"hep30145-bib-0215-20250401","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000086667","article-title":"Antihistamines in dermatology","volume":"18","year":"2005","journal-title":"Skin Pharmacol Physiol"},{"key":"hep30145-bib-0216-20250401","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1572-0241.2004.30204.x","article-title":"Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis","volume":"99","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0217-20250401","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/00365520600610154","article-title":"Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus)","volume":"41","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"hep30145-bib-0218-20250401","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jhep.2006.08.008","article-title":"Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis","volume":"45","year":"2006","journal-title":"J Hepatol"},{"key":"hep30145-bib-0219-20250401","first-page":"224","article-title":"Liver transplantation","volume":"27","year":"1993","journal-title":"J R Coll Physicians Lond"},{"key":"hep30145-bib-0220-20250401","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00042737-200111000-00022","article-title":"Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy","volume":"13","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep30145-bib-0221-20250401","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double\u2010blind, randomised, placebo\u2010controlled, crossover, phase 2a study","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"hep30145-bib-0222-20250401","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/bjo.2005.070888","article-title":"Topical ciclosporin in the treatment of ocular surface disorders","volume":"89","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"hep30145-bib-0223-20250401","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12016-007-8008-3","article-title":"Conventional therapy of Sjogren's syndrome","volume":"32","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"hep30145-bib-0224-20250401","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/0016-5085(94)90829-X","article-title":"Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?","volume":"107","year":"1994","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0225-20250401","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1572-0241.2001.03562.x","article-title":"Consecutive occurrence of primary biliary cirrhosis and autoimmune hepatitis: a case report and review of the literature","volume":"96","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0226-20250401","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"hep30145-bib-0227-20250401","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.510260508","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes","volume":"26","year":"1997","journal-title":"Hepatology"},{"key":"hep30145-bib-0228-20250401","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.510290511","article-title":"Incidence of cancer in primary biliary cirrhosis: the Mayo experience","volume":"29","year":"1999","journal-title":"Hepatology"},{"key":"hep30145-bib-0229-20250401","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cgh.2006.09.031","article-title":"Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis","volume":"5","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30145-bib-0230-20250401","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.22458","article-title":"Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep30145-bib-0231-20250401","first-page":"1208","article-title":"Practice Guidelines Committee AAftSoLD","volume":"42","year":"2005","journal-title":"Management of hepatocellular carcinoma. Hepatology"},{"key":"hep30145-bib-0232-20250401","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.12.10.830","article-title":"Portal hypertension in primary biliary cirrhosis","volume":"12","year":"1971","journal-title":"Gut"},{"key":"hep30145-bib-0233-20250401","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/01.pas.0000213286.65907.ea","article-title":"Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy","volume":"30","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"hep30145-bib-0234-20250401","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep30145-bib-0235-20250401","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/gut.2004.040832","article-title":"Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?","volume":"54","year":"2005","journal-title":"Gut"},{"key":"hep30145-bib-0236-20250401","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cgh.2007.02.031","article-title":"Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis","volume":"5","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30145-bib-0237-20250401","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep.1840200617","article-title":"Effect of distal splenorenal shunt on survival of patients with primary biliary cirrhosis","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"hep30145-bib-0238-20250401","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression","volume":"35","year":"2001","journal-title":"J Hepatol"},{"key":"hep30145-bib-0239-20250401","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep.26466","article-title":"Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep30145-bib-0240-20250401","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo\u2010controlled trial","volume":"42","year":"2005","journal-title":"Hepatology"},{"key":"hep30145-bib-0241-20250401","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0168-8278(00)80118-X","article-title":"Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial","volume":"33","year":"2000","journal-title":"J Hepatol"},{"key":"hep30145-bib-0242-20250401","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"hep30145-bib-0243-20250401","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","article-title":"Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen\/progestin","volume":"51","year":"2006","journal-title":"Dig Dis Sci"},{"key":"hep30145-bib-0244-20250401","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","year":"2002","journal-title":"Gut"},{"key":"hep30145-bib-0245-20250401","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gut.2005.079814","article-title":"Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis","volume":"55","year":"2006","journal-title":"Gut"},{"key":"hep30145-bib-0246-20250401","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","article-title":"Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers","volume":"36","year":"2002","journal-title":"J Hepatol"},{"key":"hep30145-bib-0247-20250401","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/hepr.12452","article-title":"Coronary artery disease in primary biliary cirrhosis: A systematic review and meta\u2010analysis of observational studies","volume":"45","year":"2015","journal-title":"Hepatol Res"},{"key":"hep30145-bib-0248-20250401","first-page":"2921","article-title":"Risk of incident coronary artery disease in patients with primary biliary cirrhosis","volume":"7","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"hep30145-bib-0249-20250401","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep30145-bib-0250-20250401","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00535-004-1583-7","article-title":"Long\u2010term fibrate treatment for PBC","volume":"40","year":"2005","journal-title":"J Gastroenterol"},{"key":"hep30145-bib-0251-20250401","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0016-5085(19)33896-X","article-title":"Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis","volume":"57","year":"1969","journal-title":"Gastroenterology"},{"key":"hep30145-bib-0252-20250401","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep30145-bib-0253-20250401","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","article-title":"Evolving frequency and outcomes of liver transplantation based on etiology of liver disease","volume":"95","year":"2013","journal-title":"Transplantation"},{"key":"hep30145-bib-0254-20250401","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.1840140215","article-title":"Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis","volume":"14","year":"1991","journal-title":"Hepatology"},{"key":"hep30145-bib-0255-20250401","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/BF01536666","article-title":"Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp\u2010X\u2010positive and Lp\u2010X\u2010negative subjects","volume":"33","year":"1988","journal-title":"Dig Dis Sci"},{"issue":"Suppl 2","key":"hep30145-bib-0256-20250401","first-page":"S25","article-title":"Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation","volume":"15","year":"2009","journal-title":"Liver Transpl"},{"key":"hep30145-bib-0257-20250401","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep30145-bib-0258-20250401","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/jlts.2003.50213","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history","volume":"9","year":"2003","journal-title":"Liver Transpl"},{"key":"hep30145-bib-0259-20250401","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/lt.21124","article-title":"Long\u2010term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation","volume":"13","year":"2007","journal-title":"Liver Transpl"},{"key":"hep30145-bib-0260-20250401","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/lt.20123","article-title":"Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation","volume":"10","year":"2004","journal-title":"Liver Transpl"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30145","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201901000-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T09:54:16Z","timestamp":1743674056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201901000-00032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":259,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30145","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"2018-05-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}